Ballard Spahr represented OpGen, Inc. (NASDAQ: OPGN), a molecular testing and bioinformatics company based in Gaithersburg, Maryland, in its initial public offering. OpGen today announced the pricing of its IPO of 2,850,000 units, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock, at a combined price to the public of $6 per unit. All of the units are being offered by OpGen. OpGen’s common stock and warrants have been approved for listing on the NASDAQ Capital Market under the symbols “OPGN” and “OPGNW,” respectively.

OpGen, Inc. is an early commercial stage company using molecular testing and bioinformatics to assist healthcare providers in combating multi-drug resistant bacterial infections. The company’s products and services are designed to enable the rapid identification of hospital patients who are colonized or infected with life-threatening, multi-drug resistant organisms, or MDROs. The company’s lead product is the Acuitas® MDRO Gene Test. Products in development include the Acuitas Lighthouse™ MDRO Management System and the Acuitas Resistome Test. In addition, the company has more than 10 years of experience mapping microbial, plant, and human genomes.

The Ballard Spahr team was led by Mary J. Mullany and included Peter W. Hennessey, Gerald Guarcini, Kaleena Laputka, Sandra Maki Hashima, and T. Conrad Bower.